GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » Cash Flow from Discontinued Operations

Ensol Biosciences (XKRX:140610) Cash Flow from Discontinued Operations : ₩0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Ensol Biosciences Cash Flow from Discontinued Operations?

Cash flow from discontinued operations is the cash received by a company that comes from the sale of part of business.

Ensol Biosciences's cash flow from discontinued operations for the six months ended in Dec. 2024 was ₩0 Mil. It means Ensol Biosciences received ₩0 Mil from the sale of part of business quarterly. Ensol Biosciences's cash flow from discontinued operations for the trailing twelve months (TTM) ended in Dec. 2024 was ₩0 Mil.

Ensol Biosciences Cash Flow from Discontinued Operations Historical Data

The historical data trend for Ensol Biosciences's Cash Flow from Discontinued Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensol Biosciences Cash Flow from Discontinued Operations Chart

Ensol Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Discontinued Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ensol Biosciences Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Discontinued Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Ensol Biosciences Cash Flow from Discontinued Operations Calculation

Cash received by a company that comes from the sale of part of business.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cash Flow from Discontinued Operations for the trailing twelve months (TTM) ended in Dec. 2024 was ₩0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ensol Biosciences Cash Flow from Discontinued Operations Related Terms

Thank you for viewing the detailed overview of Ensol Biosciences's Cash Flow from Discontinued Operations provided by GuruFocus.com. Please click on the following links to see related term pages.

Ensol Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » Cash Flow from Discontinued Operations
Comparable Companies
XKRX:011000 XKRX:086820 XKRX:078160 XKRX:334970 XKRX:228760 XKRX:476040 XKRX:199800 XKRX:127120 XKRX:304360 XKRX:138610 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
51, Techno 10-ro, Yuseong-gu, Daejeon, KOR, 34036
Website
http://www.ensolbio.co.kr
Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.

Ensol Biosciences Headlines

No Headlines